PubRank

VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma

Clinical Trial ID NCT00391157

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00391157

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer cell cycles. Science 1996 21.29
2 A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003 16.11
3 An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996 13.87
4 Cancer statistics, 2000. CA Cancer J Clin 2000 12.32
5 The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994 11.62
6 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998 10.77
7 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996 10.69
8 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001 6.93
9 Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001 5.87
10 Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999 5.35
11 How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999 3.34
12 Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992 3.25
13 The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995 2.17
14 Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993 2.05
15 Primary dexamethasone treatment of multiple myeloma. Blood 1992 2.02
16 Multiple myeloma. N Engl J Med 1997 1.94
17 VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990 1.87
18 Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 1977 1.58
19 Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001 1.27
20 New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995 1.23
21 The treatment of multiple myeloma. N Engl J Med 1994 1.23
22 Thalidomide--a revival story. N Engl J Med 1999 1.13
23 High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004 0.99
24 Proteasome and cell cycle. Evidence for a regulatory role of the protease on mitotic cyclins in yeast. FEBS Lett 1993 0.89
25 The role of the proteasome in cellular protein degradation. Histol Histopathol 1994 0.88
26 Treatment of myeloma. QJM 1999 0.80
27 Current drug therapy for multiple myeloma. Drugs 1999 0.78
28 Conventional chemotherapy in multiple myeloma. Pathol Biol (Paris) 1999 0.75
29 Management of Myeloma: Current and Future Approaches. Cancer Control 1998 0.75
Next 100